Manufacturer
INTAS PHARM LTD
Contents
Paclitaxel
Indication
Metastatic breast cancer/ Breast cancer/ HER2 overexpressing advanced or metastatic breast cancer/
Advanced ovarian carcinoma/ Locally advanced or metastatic non-small cell lung carcinoma/ Advanced non-small cell lung cancer/ Metastatic adenocarcinoma of pancreas/ AIDS-related Kaposi's sarcoma
Instruction
Administer via IV
Drug interaction
Increased plasma concentration and toxicity with CYP2C8 and CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, fluoxetine, clopidogrel, cimetidine, ritonavir). Decreased plasma concentration and efficacy with CYP2C8 and CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenytoin, efavirenz).
Malaysia
